在患有炎症性肠道疾病的患者中,计划外的医疗利用的长期持续改善
Gil Y Melmed1, Brant Oliver2, Alice Kennedy2
1Inflammatory Bowel and Immunobiology Research Institute, Karsh Division of Digestive and Liver Diseases, Cedars-Sinai, Los Angeles, CA, United States.
The American journal of gastroenterology
|April 7, 2025
概括
炎症性肠病 (IBD) 患者的质量改善计划持续减少了急诊室的访问和住院治疗超过三年. 这些努力证明了对患者护理和资源利用的长期益处.
科学领域:
- 胃肠病学 胃肠病学
- 医疗保健服务研究 医疗服务研究
背景情况:
- 炎症性肠病 (IBD) 的特点是不可预测的恶化,需要紧急医疗照顾.
- 在IBD管理中,急诊室 (ED) 使用率和住院率很高是常见的.
研究的目的:
- 评估在IBD的多中心质量改进 (QI) 倡议之后,ED利用的改进的长期可持续性.
- 评估QI倡议对患者报告和提供者报告结果的影响.
主要方法:
- 在最初的QI倡议之后,参与站点实施"紧急护理工具包".
- 在临床访问中对患者报告和提供者报告的结果的纵向测量.
- 持续监测急诊室使用率和住院率.
主要成果:
- 在QI倡议之后的3年里,急诊室利用率的改善持续了3年多.
- 住院治疗的减少也持续了3年多.
- "紧急护理工具包"有助于保持积极的结果.
结论:
- 持续的质量改进工作可以导致长期改善管理炎症性肠道疾病.
- 积极的策略,如"紧急护理工具包",有效地保持了减少紧急护理利用率.
- 质量改善举措对IBD患者的治疗结果和医疗资源管理产生了持久的积极影响.
相关概念视频
Inflammatory Bowel Disease V: Surgical Management
67
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
67
Inflammatory Bowel Disease IV: Pharmacological Management
82
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
82
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
253
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
253
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
91
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
91
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
108
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
108
Drugs for Treatment of Ulcerative Colitis in IBD
109
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
109


